Testing

In the second quarter of 2025, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests.

By Elizabeth Harty • July 22, 2025

Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC, explain how Mayo Clinic Laboratories' expanded test panel captures rarer as well as more common genetic causes of hereditary pancreatitis. That information is key to managing patients' enhanced risk for pancreatic cancer.

By Barbara J. Toman • July 15, 2025

Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay (Mayo ID: LBCS) improves upon standard blood tests for Wilson's disease. The new assay measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound.

By Barbara J. Toman • July 1, 2025

John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test can detect antihypertensive medications in urine, providing evidence of whether patients are actually absorbing their medications or whether a new approach might be needed.

By Barbara J. Toman • June 24, 2025

Joseph Yao, M.D., explains how Mayo Clinic Laboratories' new quantitative assay (Mayo ID: ADVQU) goes beyond qualitative testing to evaluate transplant patients for adenovirus infection. Adenovirus can cause life-threatening disease in immunocompromised transplant patients, especially children.

By Barbara J. Toman • June 17, 2025

In the first quarter of 2025, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests.

By Luci Gens • April 23, 2025

Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.

By Barbara J. Toman • April 15, 2025

Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ.

By Barbara J. Toman • April 8, 2025

Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.

By Barbara J. Toman • January 21, 2025

This will be the last CPT Codes and LOINC update. Read why.

By Michael Hutchison • January 2, 2025

Mayo Clinic Laboratories (MCL) is pleased to announce an essential update to our CPT code communication process and website layout. This change is designed to bring timely notifications for accurate billing information.

By Mayo Clinic Laboratories • December 3, 2024

This page lists updates posted to Mayo Clinic Labs during the month of November.

By Michael Hutchison • December 2, 2024

The Lupus Foundation of America estimates that at least five million people worldwide have a form of lupus. Yet, the most widely used laboratory tests for patients with this complex condition were developed more than 60 years ago, and physicians need modern, evidence-based tools to provide high-quality care for their patients. That is why Mayo Clinic Laboratories and Progentec Diagnostics joined forces to provide solutions that transform that experience.

By Jessie Fenske • November 26, 2024